Incorporating sequential
therapy into practice

Sequential Therapy Video

View this video to learn more from a
thought leader about incorporating
sequential therapy into your practice.

Administration of ZYCLARA Cream is not recommended until the skin is healed from any previous drug or surgical treatment


Value Savings for your Patients

Get details

ZYCLARA treatment in patients
previously treated with cryotherapy

Percent change from baseline of all AKs at Week 26 was 87% for cryosurgery/ ZYCLARA vs 50% cryosurgery/placebo (primary efficacy endpoints).1

  • All subjects received cryotherapy, resulting in 10 AKs left untreated; (per protocol at least 5 AKs had to be left untreated)2
  • Either ZYCLARA or placebo was initiated after a 2-week healing period2
  • A median of 11 previously undetected AKs were revealed during ZYCLARA treatment2
  • At Week 10, ZYCLARA AKs were reduced to 2 and remained unchanged until study end3
  • The placebo group remained relatively constant from the 10 AKs at treatment initiation to study end3
Dosing & Tolerability

*This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the U.S. at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted. Click here for other terms and conditions that apply.

INDICATION

ZYCLARA (imiquimod) Cream 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp in immunocompetent adults.

IMPORTANT SAFETY INFORMATION FOR ZYCLARA CREAM

Please click here for Prescribing Information, including Patient Information.

References: 1. ZYCLARA Cream Package Insert.Scottsdale, AZ: Medicis, the Dermatology Company; February 2012. 2. Data on file. Valeant Pharmaceuticals International Inc. 3. Jorizzo JL, Markowitz O,Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9(9):1101–1108.